Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index

BACKGROUND: The effect of lixisenatide—a prandial once‐daily glucagon‐like peptide‐1 receptor agonist—on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline β‐cell function, was assessed. METHODS: The 24‐week GetGoal‐M, ‐P and ‐S trials...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Metab Res Rev
Main Authors: Bonadonna, Riccardo C., Blonde, Lawrence, Antsiferov, Mikhail, Berria, Rachele, Gourdy, Pierre, Hatunic, Mensud, Mohan, Viswanathan, Horowitz, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600123/
https://ncbi.nlm.nih.gov/pubmed/28303626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dmrr.2897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados